Your browser doesn't support javascript.
loading
Nanosomal docetaxel lipid suspension based chemotherapy in a pregnant MBC patient - a case report.
Ramaswamy, Rajkumar; Joshi, Nisarg; Khan, Mujtaba A; Siddhara, Seerin.
Afiliação
  • Ramaswamy R; Department of Medical Oncology, Velammal Medical College and Research Institute, Madurai, Tamil Nadu 625009, India.
  • Joshi N; Department of Medical Affairs & Clinical Development, Intas Pharmaceuticals Ltd., Ahmedabad, Gujarat 380054, India.
  • Khan MA; Department of Medical Affairs & Clinical Development, Intas Pharmaceuticals Ltd., Ahmedabad, Gujarat 380054, India.
  • Siddhara S; Department of Medical Oncology, Velammal Medical College and Research Institute, Madurai, Tamil Nadu 625009, India.
Onco Targets Ther ; 12: 5679-5685, 2019.
Article em En | MEDLINE | ID: mdl-31406465
ABSTRACT
The current report presents a case of a pregnant woman with breast cancer metastasized to liver and lungs. The standard of care for breast cancer in pregnancy is anthracycline/taxane-based chemotherapy regimens. Docetaxel has shown a favorable toxicity profile during the second and third trimesters of pregnancy. A novel nanosomal docetaxel lipid suspension (NDLS) (DoceAqualip), with a proven efficacy and tolerability profile, has been approved in India for the treatment of advanced solid tumors since 2013. We present here a case of a pregnant woman with metastatic breast cancer managed with NDLS based TAC regimen showing a partial response after six cycles. The patient delivered a healthy male child with normal Apgar score and weight at the 32nd week of gestation.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2019 Tipo de documento: Article